focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 567.50
Bid: 567.00
Ask: 567.50
Change: -2.50 (-0.44%)
Spread: 0.50 (0.088%)
Open: 569.00
High: 571.50
Low: 560.00
Prev. Close: 570.00
DRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2022 Performance Awards - EPS Condition

19 Apr 2022 12:00

RNS Number : 5995I
Drax Group PLC
19 April 2022
 

19 April 2022

Drax Group plc

("Drax" or the "Group"; Symbol:DRX)

 

2022 Performance Awards - EPS Condition

At the time of publishing the annual report for the financial year ended 31 December 2021, Drax advised it would be separately determining, and thereafter releasing details of, the Cumulative Adjusted Earnings per Share performance condition which applies to grants made to PDMRs and other employees in the 2022 financial year.

The vesting of awards granted are subject to satisfying two performance criteria over the financial years 2022, 2023 and 2024. 50% of the awards will be measured based on Relative Total Shareholder Return relative to the FTSE-350, and the remaining 50% will be measured based on Cumulative Adjusted Earnings per Share.

Following a meeting of the Remuneration Committee, the proposed Cumulative Adjusted EPS target for 2022 has been agreed. The EPS target was set after considering the company's internal forecasts, market expectations and sector peers.

 

 

Threshold

Target

Maximum

239.5p

266.1p

292.7p

 

 

BASIS OF VESTING

Performance

Target

% of Award Vesting(of EPS performance condition)

Below threshold

0%

Threshold

239.5p

25%

Maximum

292.7p

100%

 

Vesting between the threshold and maximum will be on a straight-line basis.

The EPS target is 'Adjusted EPS', derived from Adjusted Results as reported in the Company's audited financial statements. Instances where such adjustments might apply include acquisition and restructuring costs, asset obsolescence charges and certain remeasurements on derivative contracts.

There may arise circumstances during the performance period where adjustment or discretion is applied by the Remuneration Committee by reference to exceptional items and the Remuneration Policy. The application of such adjustments would be considered during and upon completion of the performance cycle. In making their assessment, the Remuneration Committee will take into account appropriate advice (for example from our auditors, Remuneration Committee advisers or the Audit Committee) and also give due consideration to the shareholder experience. The Remuneration Committee would also take into account exceptional and unforeseen circumstances, including wider considerations such as the prevailing market environment, in assessing the appropriate level of vesting judged against the performance of the Company and management at the end of the performance period.

Total Shareholder Return relative to the FTSE-350 will be measured over the three-year period (2022-2024) consistent with the approach previously approved by shareholders.

The Remuneration Committee of Drax considers that attaining outturn at the top end of the range would represent strong performance considering the uncertain economic circumstances and the challenges to the broader economy. 

 

Ends

 

Enquiries:

Drax Investor Relations: Mark Strafford

mark.strafford@drax.com 

+44 (0) 7730 763 949

Brett Gladden, Group Company Secretarybrett.gladden@drax.com+44 (0)7936 362586

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFEFSUEESEEL
Date   Source Headline
27th Nov 20203:43 pmRNSHolding(s) in Company
19th Nov 20207:00 amRNSNew ESG RCF and Financing Update
18th Nov 20204:04 pmRNSHolding(s) in Company
6th Nov 20205:39 pmRNSSenior Secured Fixed Rate Notes due 2022
2nd Nov 20203:19 pmRNSTotal Voting Rights
2nd Nov 202012:36 pmRNSHolding(s) in Company
29th Oct 20209:38 amRNSHolding(s) in Company
28th Oct 20208:30 amRNSNotice of Change to Director Details
23rd Oct 202010:13 amRNSHolding(s) in Company
21st Oct 20204:13 pmRNSPricing of offering of Senior Secured Notes
21st Oct 202010:26 amRNSHolding(s) in Company
19th Oct 20207:10 amRNSFixed income investor calls
15th Oct 20202:57 pmRNSHolding(s) in Company
15th Oct 20202:41 pmRNSHolding(s) in Company
14th Oct 20205:31 pmRNSHolding(s) in Company
14th Oct 20205:29 pmRNSHolding(s) in Company
14th Oct 20205:28 pmRNSHolding(s) in Company
5th Oct 20204:37 pmRNSBlock listing Interim Review - Sharesave Plan
5th Oct 20204:33 pmRNSBlock listing Interim Review - PSP
5th Oct 20204:24 pmRNSBlock listing Interim Review - Bonus Matching Plan
1st Oct 20202:46 pmRNSTotal Voting Rights
14th Sep 20202:04 pmRNSInfrastructure debt facility
1st Sep 20204:45 pmRNSTotal Voting Rights
28th Aug 20209:00 amRNSHolding(s) in Company
3rd Aug 20205:21 pmRNSTotal Voting Rights
31st Jul 202011:00 amRNSDirector/PDMR Shareholding
30th Jul 202010:48 amRNSDirector/PDMR Shareholding
29th Jul 20207:00 amRNSHalf-year Report
21st Jul 202012:00 pmRNSNotice of Half Year 2020 Financial Results
17th Jul 20209:33 amRNSHolding(s) in Company
15th Jul 202010:39 amRNSHolding(s) in Company
9th Jul 20203:57 pmRNSHolding(s) in Company
7th Jul 20209:57 amRNSHolding(s) in Company
1st Jul 20202:26 pmRNSTotal Voting Rights
25th Jun 202010:57 amRNSHolding(s) in Company
23rd Jun 20202:34 pmRNSHolding(s) in Company
15th Jun 20202:21 pmRNSHolding(s) in Company
12th Jun 202011:54 amRNSHolding(s) in Company
12th Jun 20207:00 amRNS£125 million ESG facility extended to 2025
9th Jun 20203:15 pmRNSDisclosure of rights attached to equity securities
3rd Jun 20204:01 pmRNSHolding(s) in Company
1st Jun 202010:43 amRNSTotal Voting Rights
27th May 20202:30 pmRNSDirector/PDMR Shareholding
15th May 20203:00 pmRNSDirector/PDMR Shareholding
14th May 20209:00 amRNSHolding(s) in Company
11th May 20208:45 amRNSHolding(s) in Company
11th May 20207:00 amRNSDirector/PDMR Shareholding
1st May 20209:00 amRNSTotal Voting Rights
27th Apr 20209:37 amRNSHolding(s) in Company
22nd Apr 202012:45 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.